OSLO, Norway, June 17, 2019 /PRNewswire/ -- Reference is made
to the stock exchange notice published by Nordic Nanovector ASA
(the "Company") (OSE: NANO) on 31 May
2019 where the Company announced that the board of directors
of the Company had resolved to increase the Company's share capital
in connection with the exercise of RSUs.
In addition, two participants in the Company's previous share
option program, not being primary insiders, have exercised a total
number of 407,253 options through exercise of a corresponding
number of free-standing warrants. 392,255 of the options are
exercised at a strike price of NOK
25.00 per share, and 14,998 of the options are exercised at
a strike price of NOK 14.24. Each
free-standing warrant gives the right to receive one share in the
Company.
The share capital increase related to the exercise of the RSUs
and the options has been duly registered in the Norwegian Register
of Business Enterprises. Following such registration the Company's
share capital is NOK 11,022,739.20
divided into 55,113,696 shares, each with a nominal value of
NOK 0.20.
For further information, please contact:
Malene
Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37 -targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--share-capital-increase-registered,c2842215